Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR‐mutated non‐small cell lung cancer patient: A case report

A 53‐year‐old man diagnosed with disease stage IIIB pulmonary adenocarcinoma underwent chemotherapy and radiotherapy in the first‐line setting. After disease progression, he received targeted therapy because of subsequent detection of EGFR exon 19 del mutation. Following an increase in his adrenal m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiruo, Zhao, Mei, Cao, Shuliang, Zhang, Xuchao, Du, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471034/
https://www.ncbi.nlm.nih.gov/pubmed/32656988
http://dx.doi.org/10.1111/1759-7714.13569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471034/
https://www.ncbi.nlm.nih.gov/pubmed/32656988
http://dx.doi.org/10.1111/1759-7714.13569

Ejemplares similares